Correspondence 0001104659-24-091291 from Evaxion A/S (EVAX)
Evaxion A/S
Date: Aug. 20, 2024 · CIK: 0001828253 · Accession: 0001104659-24-091291
AI Filing Summary & Sentiment
File numbers found in text: 333-279153
Letter
Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Registration Statement on Form F-1 (File No. 333-279153) Acceleration Request Requested Date: August 22, 2024 Requested Time: 4:30 P.M. Eastern Time
Dear Ms. Dickerson:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form F-1 (File No. 333-279153) (the “Registration Statement”) to become effective on Thursday, August 22, 2024, at 4:30 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff (the “Staff”).
Once the Registration Statement has been declared effective, please orally confirm that event with Michael D. Baird of Duane Morris LLP by telephone at (215) 870-6771, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.
The Company understands that the Staff will consider this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate to the offering of the securities covered by the Registration Statement.
Very truly yours,
Evaxion Biotech A/S
Show Raw Text
CORRESP
1
filename1.htm
Evaxion Biotech A/S
Dr. Neergaards
Vej 5F
2970 Hørsholm
Denmark
Telephone: +45 31 31
97 53
August 20, 2024
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington D.C. 20549-4720
Attn: Jessica
Dickerson
Jason Drory
Re: Evaxion Biotech A/S
Registration Statement on Form F-1 (File
No. 333-279153)
Acceleration Request
Requested Date: August 22, 2024
Requested Time: 4:30 P.M. Eastern Time
Dear Ms. Dickerson:
In accordance with Rule 461 of Regulation
C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”)
hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause
the above-referenced Registration Statement on Form F-1 (File No. 333-279153) (the “Registration Statement”)
to become effective on Thursday, August 22, 2024, at 4:30 p.m., Eastern Time, or as soon thereafter as practicable, or at such later
time as the Registrant or its counsel may orally request via telephone call to the staff (the “Staff”).
Once the Registration Statement has been declared
effective, please orally confirm that event with Michael D. Baird of Duane Morris LLP by telephone at (215) 870-6771, or if you have any
questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.
The Company understands that the Staff will consider
this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate
to the offering of the securities covered by the Registration Statement.
Very truly yours,
Evaxion Biotech A/S
By:
/s/ Christian Kanstrup
Christian Kanstrup
Chief Executive Officer
cc:
Michael D. Baird, Duane Morris LLP
Lars Lüthjohan
Jensen, Mazanati-Andersen
2